Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0)
Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0)
复制标题
DOI：
10.1007/s10147-015-0819-2
复制
发表时间：
2015-10-01
影响因子：
3.3
通讯作者：
Nagata, Yasushi
中科院分区：
文献类型：
--
作者：
Murakami, Yuji;Takahashi, Ippei;Nagata, Yasushi
回顾性分析2001年至2011年期间，经组织学证实的无区域和远处转移的食管粘膜下癌患者接受确定性同步放化疗的长期结局。放射治疗的中位数总剂量为60戈伊/30次（范围，54-66戈伊）与选择性淋巴结照射40戈伊同时结合5-呋喃脲嘧啶为基础的化疗。36例患者（33名男性和3名女性），年龄从45岁到80岁（中位数，67岁）进行了评估。所有患者均患有鳞状细胞癌。中位随访时间为61个月，5年总生存率、无病生存率和局部无失败生存率分别为86%[95%置信区间（CI），74- 99%]、59%（95% CI，42- 77%）和90%（95% CI，79- 100%）。观察到2例患者发生3级胸腔积液、1例患者发生4级心包积液和1例患者发生5级肺炎的晚期毒性。异时性食管癌8例（22%）.其中6例粘膜下癌患者通过内镜切除术得以挽救。我们对食管粘膜下癌患者进行同步放化疗（CCRT）的长期结果显示，在维持器官保存的同时，毒性可接受，局部控制和生存率良好。
The long-term outcomes of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer without regional and distant metastasis were retrospectively analyzed.Patients with histologically confirmed esophageal submucosal cancers without regional and distant metastasis who received definitive concurrent chemoradiotherapy from 2001 to 2011 were included. Radiation therapy of a median total dose of 60 Gy/30 fractions (range, 54-66 Gy) with elective nodal irradiation of 40 Gy was combined concurrently with 5-furuorouracil-based chemotherapy.Thirty-six patients (33 men and 3 women) aged from 45 to 80 years (median, 67 years) were assessed. All patients had squamous cell carcinoma. With a median follow-up time of 61 months, the 5-year overall survival, disease-free survival, and locoregional failure-free survival rates were 86 % [95 % confidence interval (CI), 74-99 %], 59 % (95 % CI, 42-77 %), and 90 % (95 % CI, 79-100 %), respectively. Late toxicities of grade 3 pleural effusion in 2 patients, grade 4 pericardial effusion in 1 patient, and grade 5 pneumonitis in 1 patient were observed. Metachronous esophageal cancer was observed in 8 patients (22 %). Among them, 6 patients with mucosal legions were salvaged by endoscopic resection.Our long-term results of concurrent chemoradiotherapy (CCRT) for patients with esophageal submucosal cancer showed acceptable toxicities and favorable locoregional control and survivals while maintaining organ preservation.